At a glance
- GHRH 1-44 (somatorelin) is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 114 publications mentioning it, including 14 randomized controlled trials and 8 animal-only studies.
- ClinicalTrials.gov lists 1 registered study testing it (0 active).
- FDA's adverse event system (FAERS) holds 5 reports mentioning it; 3 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models.
- Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
- Results of a 5-Year N-of-1 Growth Hormone Releasing Hormone Gene Therapy Experiment.
- The intra-individual stability of GH biomarkers IGF-I and P-III-NP in relation to GHRH administration, menstrual cycle, and hematological parameters.
- Native Chemical Ligation-Photodesulfurization in Flow.
- Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.
- Synthesis and biological evaluation of novel structure-related hGHRH agonistic analogs.
- Identification of the growth hormone-releasing hormone analogue [Pro1, Val14]-hGHRH with an incomplete C-term amidation in a confiscated product.
- Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
- Effectiveness of GH isoform differential immunoassay for detecting rhGH doping on application of various growth factors.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 1
- Active
- 0
- With posted results
- 1
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese | Completed | Phase 2 | Jul 2008 |
All 1 study on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 5
- Serious
- 3
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.